Tag Archives: scbt

Feedback Plc – Presentation of Study Results

On July 20^th 2015, Feedback plc announced the successful completion of a large evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy imaging biomarker in 241 metastatic renal (kidney) cell cancer (m-RCC) patients treated with anti-angiogenic therapy (AAT – drugs that block cancer blood-vessel growth).

The research study was led by Dr. Andrew Smith (Associate Professor in Radiology and Director of Radiology Research) along with colleagues from the University of Mississippi Medical Center, Jackson, Mississippi, USA (UMMC).

Specifically the results from this large study demonstrated that TexRAD texture analysis on conventional CT imaging acquired before m-RCC patients underwent AAT was a very strong predictor of overall survival at 2 years. Dr. Smith and colleagues further demonstrated that in a multivariate model comprising of known clinical biomarkers in this cancer population, TexRAD CTTA additionally demonstrated to be a strongly independent predictor of overall survival. The authors have developed a “new prognostic risk index” comprising of TexRAD CTTA and other known clinical factors which has demonstrated superior accuracy in predicting patient survival and classified patients into low, medium and high-risk groups with strong statistical significance (p<0.0001). Dr. Smith and colleagues also concluded that pre-therapy TexRAD CTTA is a significant prognostic marker in patients with m-RCC treated with AAT.

On October 7^th-11^th, 2015 Dr Andrew Smith presented the data from this large patient study (n=241) on the use of TexRAD texture analysis on CT scans in predicting survival in secondary kidney cancer patients treated with anti-vascular drugs.

The presentation at the Society of Computed Body Tomography and Magnetic Resonance (SCBT-MR) Conference was awarded the Best Junior Researcher Presentation. Below are some slides from the presentation.